Literature DB >> 35938462

HIV and cardiovascular disease: the role of inflammation.

Sahera Dirajlal-Fargo1,2, Nicholas Funderburg3.   

Abstract

PURPOSE OF REVIEW: HIV and antiretroviral therapy (ART) use are linked to an increased incidence of atherosclerotic cardiovascular disease (ASCVD). Immune activation persists in ART-treated people with HIV (PWH), and markers of inflammation (i.e. IL-6, C-reactive protein) predict mortality in this population. This review discusses underlying mechanisms that likely contribute to inflammation and the development of ASCVD in PWH. RECENT
FINDINGS: Persistent inflammation contributes to accelerated ASCVD in HIV and several new insights into the underlying immunologic mechanisms of chronic inflammation in PWH have been made (e.g. clonal haematopoiesis, trained immunity, lipidomics). We will also highlight potential pro-inflammatory mechanisms that may differ in vulnerable populations, including women, minorities and children.
SUMMARY: Mechanistic studies into the drivers of chronic inflammation in PWH are ongoing and may aid in tailoring effective therapeutic strategies that can reduce ASCVD risk in this population. Focus should also include factors that lead to persistent disparities in HIV care and comorbidities, including sex as a biological factor and social determinants of health. It remains unclear whether ASCVD progression in HIV is driven by unique mediators (HIV itself, ART, immunodeficiency), or if it is an accelerated version of disease progression seen in the general population.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35938462      PMCID: PMC9370832          DOI: 10.1097/COH.0000000000000755

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.061


  97 in total

1.  Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Authors:  Steven K Grinspoon; Kathleen V Fitch; Edgar Turner Overton; Carl J Fichtenbaum; Markella V Zanni; Judith A Aberg; Carlos Malvestutto; Michael T Lu; Judith S Currier; Craig A Sponseller; Myron Waclawiw; Beverly Alston-Smith; Katharine Cooper-Arnold; Karin L Klingman; Patrice Desvigne-Nickens; Udo Hoffmann; Heather J Ribaudo; Pamela S Douglas
Journal:  Am Heart J       Date:  2019-03-04       Impact factor: 4.749

2.  Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.

Authors:  Ninad S Chaudhary; Tobias Kind; Amanda L Willig; Michael S Saag; Sadeep Shrestha; Nicholas Funderburg; Howard W Wiener; E Turner Overton; Marguerite R Irvin
Journal:  Medicine (Baltimore)       Date:  2021-07-30       Impact factor: 1.817

3.  FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease.

Authors:  Nicola Martinelli; Domenico Girelli; Giovanni Malerba; Patrizia Guarini; Thomas Illig; Elisabetta Trabetti; Marco Sandri; Simonetta Friso; Francesca Pizzolo; Linda Schaeffer; Joachim Heinrich; Pier Franco Pignatti; Roberto Corrocher; Oliviero Olivieri
Journal:  Am J Clin Nutr       Date:  2008-10       Impact factor: 7.045

4.  Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.

Authors:  Jyoti S Mathad; Nikhil Gupte; Ashwin Balagopal; David Asmuth; James Hakim; Breno Santos; Cynthia Riviere; Mina Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Noluthando Mwelase; Jyoti Pawar; Sima Berendes; Nagalingeswaran Kumarasamy; Bruno B Andrade; Thomas B Campbell; Judith S Currier; Susan E Cohn; Amita Gupta
Journal:  J Acquir Immune Defic Syndr       Date:  2016-10-01       Impact factor: 3.731

Review 5.  Weighing in on the risks and benefits of probiotic use in HIV-infected and immunocompromised populations.

Authors:  A U Happel; S L Barnabas; R Froissart; J S Passmore
Journal:  Benef Microbes       Date:  2018-01-18       Impact factor: 4.205

6.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

7.  Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy.

Authors:  Mehwish Younas; Christina Psomas; Christelle Reynes; Renaud Cezar; Lucy Kundura; Pierre Portalès; Corinne Merle; Nadine Atoui; Céline Fernandez; Vincent Le Moing; Claudine Barbuat; Albert Sotto; Robert Sabatier; Audrey Winter; Pascale Fabbro; Thierry Vincent; Jacques Reynes; Pierre Corbeau
Journal:  Front Immunol       Date:  2021-03-30       Impact factor: 7.561

8.  Relationship between economic insecurity, inflammation, monocyte activation and intestinal integrity in children living with HIV in Uganda.

Authors:  Sahera Dirajlal-Fargo; Zainab Albar; Abdus Sattar; Manjusha Kulkarni; Emily Bowman; Nicholas Funderburg; Rashidah Nazzinda; Cissy Kityo; Victor Musiime; Grace A McComsey
Journal:  AIDS Care       Date:  2020-06-15

Review 9.  Defining trained immunity and its role in health and disease.

Authors:  Mihai G Netea; Jorge Domínguez-Andrés; Luis B Barreiro; Triantafyllos Chavakis; Maziar Divangahi; Elaine Fuchs; Leo A B Joosten; Jos W M van der Meer; Musa M Mhlanga; Willem J M Mulder; Niels P Riksen; Andreas Schlitzer; Joachim L Schultze; Christine Stabell Benn; Joseph C Sun; Ramnik J Xavier; Eicke Latz
Journal:  Nat Rev Immunol       Date:  2020-03-04       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.